There are seven ratings firms that have a “buy” for Integra, with two equities analysts have the stock rated at a “hold”
Here are five quick facts about Integra LifeSciences stock:
• Average on-year target price among covering brokers is $61
• Barclays analysts raised their price target from $50 to $60
• Oppenheimer analysts reiterated their “outperform” rating and set a $62 price target
• Argus raised their price target from $55 to $61 with a “buy” rating on Feb. 13
• Integra has a $1.9 billion market cap and 58.26 price-to-earnings ratio
More articles on orthopedic device:
SI-BONE reaches 15k iFuse procedures—5 things to know
Globus Medical, Aurora Spine, NuVasive & more—22 key notes
Spine device company stock report: 5 key companies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
